Tammy Pham

Dr. Tammy Pham

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 May 2022 in Cardiology in the Young
Verified
Journal Article
Closed access
PDF file
SSSharnendra K. Sidhu
Sharnendra K. Sidhu
LMLaura J. McLaughlin
Laura J. McLaughlin
TPTammy Pham
Tammy Pham
BLBojan Lazarevic
Bojan Lazarevic
EKElana R. Kriegel
Elana R. Kriegel
RMRuth Milanaik
Ruth Milanaik
A 2012 American Heart Association statement concluded that children with CHD are at an increased risk for neurodevelopmental delays. Routine surveillance and evaluation throughout childhood are recommended. To assess paediatric cardiologist compliance with American Heart Association guidelines and developmental referral practices, a survey was distributed to paediatric cardiologists nationwide (n = 129). The majority of participants (69%) stated they were somewhat familiar or not familiar with the American Heart Association statement and were concerned about patients not being properly referred to specialists for developmental evaluation. Forty paediatric cardiologists (31%) indicated that their institution did not have a neurodevelopmental cardiology programme. Of these, 25% indicated they generally did not refer CHD patients for neurodevelopmental evaluation, 45% performed surveillance and referred if warranted, and 30% generally referred all patients for surveillance. Lastly, 43% of paediatric cardiologists did not feel responsible for developmental surveillance, and 11% did not feel responsible for referrals. To ensure all children with CHD are appropriately screened and referred, paediatricians and cardiologists must work together to address differing impressions of accountability for surveillance and screening of children with CHD.

7 November 2024 in Bioengineering
Verified
Journal Article
Open access
PDF file
TPTammy Pham
Tammy Pham
RSRobert Sah
Robert Sah
KMKoichi Masuda
Koichi Masuda
Deborah WatsonDeborah Watson
Deborah Watson
Nasal septal cartilage tissue engineering is a promising and dynamic field with the potential to provide surgical options for patients with complex reconstruction needs and mitigate the risks incurred by other tissue sources. Developments in cell source selection, cell expansion, scaffold creation, and three-dimensional (3D) bioprinting have advanced the field in recent years. The usage of medicinal signaling cells and nasal chondroprogenitor cells can enhance chondrocyte proliferation, stimulate chondrocyte growth, and limit chondrocyte dedifferentiate. New scaffolds combined with recent innovations in 3D bioprinting have allowed for the creation of more durable and customizable constructs. Future developments may increase technical accessibility and manufacturability, and lower costs, to help incorporate these methods into pre-clinical studies and clinical applications of septal cartilage tissue engineering.

26 February 2023 in Facial Plastic Surgery Clinics of North America
Verified
Journal Article
Closed access
TPTammy Pham
Tammy Pham
JGJacqueline J Greene
Jacqueline J Greene

1 January 2018 in Pediatrics
Verified
Conference Paper
Closed access
TPTammy Pham
Tammy Pham
AHAlexandra Hua
Alexandra Hua
DLDiana Li
Diana Li
SBSari Bar
Sari Bar
RSRegina Spinazzola
Regina Spinazzola
RMRuth Milanaik
Ruth Milanaik

31 December 2025 in Cancers
Verified
Journal Article
Open access
PDF file
THTara Hosseini
Tara Hosseini
LHLaura Ho
Laura Ho
TPTammy Pham
Tammy Pham
AMAlfredo Alberto Molinolo
Alfredo Alberto Molinolo
RJRiley Jones
Riley Jones
TGTheresa Guo
Theresa Guo
Background/Objectives: Non-melanoma skin cancer, which includes cutaneous squamous cell carcinoma (cSCC), ranks as the 5th most common cancer globally with high morbidity and more total deaths than melanoma despite having a lower mortality rate. While most cSCC cases can be treated with surgery, locally advanced, metastatic, and high-risk cSCC tumors are associated with a worse prognosis with higher rates of recurrence and require multimodality therapy. However, there is limited data on animal models of cutaneous squamous cell carcinoma for the use of combinatory immunotherapy and radiation. Methods: In this study, spontaneously generated tumors using DMBA/TPA were treated over three weeks with either IgG control, anti-PD1 antibody monotherapy, 8 Gy of localized radiation, or a combination of anti-PD1 and 8 Gy of radiation followed by anti-PD1 therapy. Results: We found that while anti-PD1 therapy showed a trend toward slowed tumor growth compared to controls, this difference was not statistically significant (p = 0.0775), with most mice showing continued tumor progression. Preliminary histological analysis suggested that anti-PD1 treatment increased CD8+ T cell infiltration, and the addition of radiation further enhanced CD8+ responses but added greater variability. A pathologic review revealed that irradiated tumors were associated with fibroblastic spindle-like cell morphology. Conclusions: This animal model represents a potential preclinical model for studying CSCC with limited responses to immunotherapy to understand potential mechanisms of resistance.